Pradimicins Tl and T2 are new members of the pradimicin family of antibiotics produced by an actinomycete strain AA3798.Pradimicins Tl and T2 are dihydrobenzo|>]naphthacenequinones substituted with 3 and 2 sugar moieties, respectively. The salient feature in their structures is an L-xylose attached to the phenolic hydroxyl group at C-ll. Bioconversion experiments using a blocked mutant B-54 of strain AA3798 not only explored a plausible biosynthetic pathway of pradimicins Tl and T2, but also provided evidence of 5S,6S configuration.
138.1 (s) 2 ' 3.73 (dd, 7.70, 9.40) 70.0 (d) 5 4.52 (d, 10 .26) 81.2 (d) 3' 3.56 (dd, 9.40, 2.99 (3 104.2ppm ) and from 3'-H (3 3.56ppm) to C-l" (3 105.0ppm ). The attachment of the second xylose to the phenolic hydroxyl group at C-l l was ascertained by the observed NOEsbetween 1"'-H (3 5.17ppm) and 10-H (3 6.98ppm) and between 1"'-H and 12-H (3 7.38ppm ) in the NOESYspectrum of PRM Tl, and confirmed by converting PRM Tl into ll-0-dexylosylpradimicin Tl (2) (FAB-MS m/z 800 (M+H)+; IR 1730 and 1620cm"1) by mild alkaline hydrolysis. The stereochemical identities of the 3 sugars were proved by comparing the methylglycoside-2,3,4triacetates isolated from the degradation (methanolysis/acetylation) products of PRMTl and 2 with authentic samples. The methyl a-fucopyranoside-2,3,4-triacetate isolated from the degradation products of PRMTl gave an [a]fs7 value of + 145°(c 2.42, CHC13), which corresponds to the D-isomer (Lit.4) Md2= + 146°), indicating D-configuration of the fucose at C-5. Since PRMTl apparently gave racemic methyl a-xylopyranoside-2,3,4-triacetate, 2 was subjected to the same degradation sequence. The methyl a-xylopyranoside-2,3,4-triacetate derived from 2 gave an [a]^7 value of + 116°(c 1.30, CHC13), which corresponds to the D-isomer (Lit.4) [a]o2 = + 121°), indicating D-configuration of the xylose at C-3'. The L-configuration of the xylose at C-ll was ascertained by the XHNMR experiments on the methyl a-xylopyranoside-2,3,4-triacetate derived from PRMTl using a chiral shift reagent, (S>(+)-2,2,2trifluoro-l-(9-anthryl)ethanol.
The XHNMRspectrum in CDC13 in the presence of 5 equiv of the chiral reagent showed a pair of OCH3signals at 3 3.38 and 3.39ppm, where the signal at 3 3.39ppm was enhanced by the addition of the authentic sample of methyl a-L-xylopyranoside-2,3,4-triacetate.
Structure of PRMT2
The molecular formula of PRMT2 determined as C37H37NO19from the FAB-MS(positive) peak Found: C 52.75, H 5.00, N 1.95) was confirmed by the 13CNMRmeasurement. Comparison of the spectral data of PRMT2 with those of PRMTl allowed us to assign the lH and 13C NMRsignals ( Table 2 ) and the structure of PRMT2 (Fig. 2 ). The attachment of the fucose moiety to C-5 was based on the^-^C long range coupling from 5-H (S 4.38) to C-l' (S 104.9) and the attachment of the xylose moiety to C-ll came was confirmed by converting PRMT2 into ll-0-dexylosylpradimicin T2 (3) (FAB-MS m/z 668 (M+H)+; IR 1730 and 1610cm"1).
The stereochemistry of the sugar moieties in PRMT2 was established by degradation experiments. The methyl a-fucopyranoside-2,3,4-triacetate and methyl a-xylopyranoside-2,3,4-triacetate isolated from the degradation products of PRM T2 gave [a]£8 values of 4-119°(c 2.10, CHC13) and -108°(c 2.05, CHC13), respectively, indicating D-fucose at C-5 and L-xylose at C-l l.
The presence of the L-xylose moiety in PRMTl and PRMT2 is quite unusual, since no natural products containing such sugar have ever been reported in literature.
Biosynthesis ofPRM Tl and PRMT2 During the biosynthetic studies on PRMA5~7), we isolated blocked mutants JN-219 and JN-213 of Actinomadura verrucosospora subsp. neohibisca E-40, a high PRMA-producer. The mutant JN-219 produces 1 1-O-demethylpradinone ll (4), 7-O-methyl-l l-O-demethylpradinone II (5) and 1 1-O-demethylpradinone I (6), while the mutant JN-213 is able to convert these aglycones into PRMA, providing definite evidence for the biosynthetic pathway from 4 to PRMA through 5 and 6. Since these aglycones APR. 1993 Method: Strain B-54 was preincubated at 28°C for 48 hours in 4ml of medium composed of glucose 3%, Bact soytone 1.5% and CaCl2 -2H2O 0.05%, and 4 at a final concentration of 0.8/im was added. Incubation was continued for additional 30hours and the fate of 4 was monitored by HPLCon YMC-ODSA 301-5 (4.6 i.d. x 100mm) using acetonitrile-0.1M phosphate buffer (17~25:83~75, pH 3.5) as eluent at a flow rate of 1 ml/minute with detection at 460 nm.
contain a phenolic hydroxyl group at C-ll, we became interested in the biosynthetic pathway of PRMTl and PRMT2 in order to understand producer-metabolite relationships.
A blocked mutant B-54 selected for microbial conversion was generated from strain AA3798by TV-methyl-TV'-nitro-TV-nitrosoguanidine treatment. The mutant B-54 was preincubated at 28°C for 48 hours in a medium composed of glucose 3%, soytone 1.5% and CaCl2-2H2O 0.05%. The possible biosynthetic intermediates of PRMTl including PRMT2 at a final concentration of 0.5~0.8fiu were separately fed to the growing culture and incubation was continued for additional 307 2hours. Since strain B-54 did not produce any detectable amount of pradimicins apparently due to the block in the early part of the biosynthetic pathway, the fate of these intermediates was readily monitored by HPLC. Table 4 summarizes the results of similar bioconversion experiments with 8 potential intermediates of PRMTl. The efficient conversion of these intermediates allowed us to propose a plausible biosynthetic pathway of PRMTl and PRMT2 (Fig. 2) .
The bioconversion experiments presented here provided evidence that both PRMTl and PRMT2 have 5S,6S configuration since the stereochemistry of 5 has been denned previously6). Whenthe biosynthetic pathway of PRMTl and PRMT2 is compared with that of PRMA, the major difference is the step introducing a substituent at C-ll after incorporation of the amino acid side chain. It is also important to note that the L-xylosyl moiety is introduced into both 2 and 3. This implies the possibility of microbial modification of pradimicin analogs and derivatives having a phenolic hydroxyl group at C-ll using the mutant B-54.
Ex pe rime nt al
General Procedures
The melting points are uncorrected. Spectral data were recorded on the following instruments: XH and 13C NMR, JEOL JMN-GX 400; IR, JASCO IR-810 spectrometer;
UV-vis, JASCO UVIDEC-610 spectrometer; low and high resolution FAB-MS, JEOL JMS-AX505H spectrometer; optical rotation, JASCO DIP-140 digital polarimeter.
For TLC analysis, E. Merck precoated Kieselgel 60F254 plates (0.25 mm) were used.
Methanolysis of PRMTl
A solution ofPRM Tl (300mg) in 50ml of 10% HCl-MeOHwas refluxed for 3 hours. The reaction mixture was cooled, filtered and the filtrate was concentrated in vacuo. The residue was dissolved in 1 ml of acetic anhydride and 2ml of pyridine, and stirred at 25°C for 15 hours. The solvent was removed in vacuo and the residue chromatographed on a column of silica gel (Kieselgel 60, 230~400mesh) using 1 : 7 acetone -hexane as eluent to give 12mg of methyl a-D-fucopyranoside-2,3,4-triacetate:
[a]p7 = + 145°( c 2.42, CHC13); FAB-MS m/z 305 (M+H)+, and 24mg of racemic methyl a-xylopyranoside-2,3,4triacetate:
FAB-MS m/z 291 (M+H)+. The *H NMRspectrum in CDC13 showed signals at S 2.02 (6H, s, 2xOAc), 2.07 (3H, s, OAc), 3.39 (3H, s, OCH3), 3.58 (1H, t, /=10.7Hz, Hax at C-5), 3.79 (1H, dd, .7=10.7, 6.0Hz, Heq at C-5), 4.83 (1H, dd, ,7=9.8, 3.4Hz, 2-H), 4.88 (1H, d, /=3.4Hz, 1-H), 4.96 (1H, ddd,.7=10.7, 9.8, 6 .0Hz, 4-H) and 5.47 (1H, t, /=9.8Hz, 3-H). Addition of 5 equiv of (£)-(+)-2,2,2-trifluoro-l-(9-anthryl)ethanol resolved the peaks at S 3.58, 3.79 and 3.39. The aglycone solidified in the methanolysis product was collected by filtration, washed with MeOH and redissolved in 10ml of 1 n NaOH. The solution was stirred at 25°C for 15 hours and acidified with In HC1. The solid formed was collected by filtration and dried to give 100mg of 1: MP 200~210°C; FAB-MS m/z 522 (M+H)+, IR 1730 and 1620cm"1; UV Amax (0.02n NaOH-MeOH) 247, 308 and 504nm; XH NMR 6 (DMSO-d6-D2O) 2.36 (3H, s), 3.91 (2H, s), 4.22 (1H, d), 4.28 (1H, d), 6.65 (1H, d), 7.08 (1H, s), 7.22 (1H, d) and 8.09 (1H, s).
Alkaline Hydrolysis of PRM Tl
A solution ofPRM Tl (500mg) in 80ml of 1 n NaOH was heated at 65°C for 7 hours. The reaction mixture was cooled and adjusted to pH 3.0 with 6n HC1. The solid formed was collected by centrifugation (3,000rpm) 3.94 (2H, d), 4.44 (1H, d), 4.52 (1H, d), 4.61 (1H, d), 4.63 (1H, d), 6.65 (1H, d), 7.21 (1H, s), 7.24 (1H, d), 8.07 (1H, s), 8.36 (1H, t, exchangeable with D2O).
Methanolysis of 2
A solution of2 (250mg) in 50ml of 10% HC1-MeOHwas refluxed for 3 hours. The reaction mixture was cooled, filtered and the filtrate was concentrated in vacuo. The residue was acetylated in 1 ml of acetic anhydride and 2ml of pyridine at 25°C for 15 hours. The solvent was removed in vacuo and the residue chromatographed on silica gel using 1 : 7 acetone -hexane to give 15.6mg of methyl a-D-xylopyranoside-2,3,4-triacetate:
[a]£7= + 116°; FAB-MS m/z 291 (M+H)+, and 29.1 mg of methyl a-D-fucopyranoside- APR. 1993 2,3 ,4-triacetate.
Alkaline Hydrolysis of PRMT2 A solution of PRM T2 (300mg) in 50ml of 1 n NaOHwas heated at 65°C for hours. The reaction mixture was cooled and adjusted to pH 3.0 with 6n HC1. The solid formed was collected by centrifugation (3,000rpm) and purified by chromatography on a column of YMCGELODS-A60 (1.1 liters) using acetonitrile-0.01 m phosphate buffer (7 : 93, pH 3.5) as eluent to afford 3 (180mg, 72% exchangeable with D2O).
Methanolysis of PRM T2
A solution of PRMT2 (300mg) in 60ml of 10% HCl-MeOH was refluxed for 1.5hours. The reaction mixture was cooled, filtered and the filtrate was concentrated in vacuo. The residue was dissolved in lml of acetic anhydride and 2ml of pyridine, and stirred at 25°C for 15hours. The solvent was removed in vacuo and the residue chromatographed on a column of silica gel (Kieselgel 60) using 1 : 7 acetone -hexane as eluent to give 23.3 mg of methyl a-D-fucopyranoside-2,3,4-triacetate:
[ci]á" = + \ \9°( c 2.10, CHC13); FAB-MS m/z 305 (M +H)+, and 20.9mg of methyl a-L-xylopyranoside-2,3,4-triacetate:
[a]28= _108o (C 2.05, CHCI3); FAB-MS m/z 291 (M+H)+.
5-0-Defucosylpradimicin T2 (7) 5-O-Defucosylpradimicin T2 (7) was produced by a blocked mutant B-10 derived from Actinomadura sp. AB12368). Strain B-10 was preincubated at 28°C for 3 days in ten 500-ml Erlenmeyer flasks containing 100ml of medium composed of glucose 2%, Pharmamedia (Traders Protein) 1% and KH2PO4 0.1% on a rotary shaker (200rpm). PRMT2 at a final concentration of lOO^g/ml was added to the flasks and incubation was continued for additional 1 1 days. The fermentation broth was centrifuged at 3,000rpm for 20 minutes and the supernatant (850ml) mixed with 500ml of Diaion HP-20. The resin was washed with 2 liters of water, and the product was eluted with 1.5 liters of 60%aq acetone. The eluate was concentrated in vacuo and the aq residue was chromatographed on a column of YMC GELODS-A60 (1.5 liters, YMCCo., Ltd.) using acetonitrile-0.01 m phosphate buffer (12: 88, pH 5.1) as eluent. The fractions containing the major product were combined and concentrated in vacuo, and the aq residue was mixed with 30ml of Diaion HP-20. The resin was washed with 300ml of water and the product eluted with 100ml of 60%aq acetone. The acetone was removed in vacuo and the aq residue lyophilized to give 65.9mg of7: FAB-MSm/z 653 (M +H)+. The^NMRspectrum in DMSO-</6 -D2O showed one-proton doublet at S 5.18 (.7=7.27Hz) assignable to the anomeric proton of the xylose moiety at C-ll.
